Oriental Insight | Professor Juliang Zhang: Insights into Adjuvant Intensified Therapy for HR+/HER2- Breast Cancer

Oriental Insight | Professor Juliang Zhang: Insights into Adjuvant Intensified Therapy for HR+/HER2- Breast Cancer

2025.10.21
Hormone receptor–positive, HER2-negative (HR+/HER2−) breast cancer is the most common molecular subtype of breast cancer. Although patients with this subtype generally have a favorable prognosis, its high heterogeneity means that some individuals remain at risk of disease recurrence.In recent years, adjuvant treatment strategies have been continuously refined — evolving from standard endocrine therapy to the incorporation of CDK4/6 inhibitors — significantly improving patient outcomes.In this edition of Oncology Frontier, Professor Juliang Zhang from the Department of Breast, Thyroid, and Vascular Surgery, Xijing Hospital, Air Force Medical University, shares his insights on adjuvant intensified therapy for HR+/HER2− breast cancer.
A New Breakthrough in Urothelial Carcinoma Treatment — Professor Dingwei Ye from Fudan University Cancer Hospital Leads a Groundbreaking Clinical Study 

A New Breakthrough in Urothelial Carcinoma Treatment — Professor Dingwei Ye from Fudan University Cancer Hospital Leads a Groundbreaking Clinical Study 

2025.10.16
Approximately 5% of urothelial carcinoma (UC) patients present with distant metastasis at diagnosis, and 30% of early-stage patients relapse or develop metastasis despite active treatment. With the emergence of antibody-drug conjugates (ADCs), the median survival of advanced UC patients has extended to 31.5 months. However, the overall survival remains suboptimal. To address this challenge, Professor Dingwei Ye and his team at Fudan University Cancer Hospital initiated a phase II clinical trial of BL-B01D1 for locally advanced or metastatic UC in 2023. The study was presented orally at the 2024 European Society for Medical Oncology (ESMO) Congress, and recently published in the Journal of Clinical Oncology (JCO, IF 41.6).
ISEH 2025 | Professor Toshio Suda on the Core Highlights of the Conference and the Frontiers of Hematopoietic Stem Cell Research

ISEH 2025 | Professor Toshio Suda on the Core Highlights of the Conference and the Frontiers of Hematopoietic Stem Cell Research

2025.10.14
The 54th Annual Scientific Meeting of the International Society for Experimental Hematology (ISEH 2025) was held from September 24–27, 2025, in Kumamoto, Japan. As one of the most prestigious international conferences in the field of hematology, this year’s meeting gathered leading experts from around the world to engage in in-depth discussions on the latest advances in basic hematology, immunology, stem cell research, and cell and gene therapy. During the conference, Oncology Frontier – Hematology Frontier had the privilege of interviewing Professor Toshio Suda, former President of ISEH and Distinguished Professor at Peking Union Medical College, who shared his insights on the major highlights of the meeting and the latest developments in stem cell research.
Professor Xu Danfeng: Moving Beyond the “One-Size-Fits-All” Approach — Achieving Maximal Nephron Preservation for Hilar Renal Tumors Through TAPD Technology and Personalized Suturing — The Chinese Solution | 2025 Pujiang Uro-Oncology Academic Conference 

Professor Xu Danfeng: Moving Beyond the “One-Size-Fits-All” Approach — Achieving Maximal Nephron Preservation for Hilar Renal Tumors Through TAPD Technology and Personalized Suturing — The Chinese Solution | 2025 Pujiang Uro-Oncology Academic Conference 

2025.10.12
Editor’s Note:In recent years, new diagnostic and therapeutic innovations in renal cancer have continued to emerge, providing clinicians with a growing range of treatment options. The widespread adoption of robot-assisted partial nephrectomy (RAPN) has enabled patients to achieve both oncological control and functional preservation. During the 2025 Pujiang Uro-Oncology Academic Conference, leading domestic and international experts in uro-oncology gathered to explore cutting-edge advances and surgical innovations in renal cancer. In this interview, Professor Xu Danfeng from Ruijin Hospital, Shanghai Jiao Tong University School of Medicine, shares insights from his team’s pioneering surgical concepts and techniques for managing complex hilar renal tumors, offering valuable perspectives for peers in the field.